Skip to main content
. Author manuscript; available in PMC: 2011 Mar 9.
Published in final edited form as: J Clin Oncol. 2008 Jun 20;26(18):2959–2965. doi: 10.1200/JCO.2007.15.1928

Table 4.

Adverse events

A. Cohort 1 (n=63)
Event Grade 1 Grade 2 Grade 3 Grade 4 Total
Fatigue 54 (86%) 3(5%) 0 (0%) 0 (0%) 57 (91%)
Hot flashes 37 (59%) 4 (6%) 0 (0%) 0 (0%) 41 (65%)
Neuropathy 26 (41%) 0 (0%) 0 (0%) 0 (0%) 26 (41%)
Febrile Neutropenia 0 (0%) 0 (0%) 4 (6%) 5 (8%) 9 (14%)
Neutropenia 1 (2%) 3 (5%) 9 (14%) 28 (44%) 41 (65%)
Hyperglycemia 15 (24%) 25 (40%) 14 (22%) 0 (0%) 54 (86%)
Mental Status Change 0 (0%) 0 (0%) 1 (1.6%) 0 (0%) 1 (1.6%)
B. Cohort 2 (n=39)
Event Grade 1 Grade 2 Grade 3 Grade 4 Total
Fatigue 33 (85%) 5 (13%) 0 (0%) 0 (0%) 38 (98%)
Hot flashes 29 (74%) 1 (3%) 0 (0%) 0 (0%) 30 (77%)
Neuropathy 23 (59%) 2 (5%) 0 (0%) 0 (0%) 25 (64%)
Febrile Neutropenia 0 (0%) 0 (0%) 6 (15%) 1 (3%) 7 (18%)
Neutropenia 0 (0%) 5 (13%) 6 (15%) 16 (41%) 27 (70%)
Hyperglycemia 10 (26%) 20 (51%) 8 (21%) 0 (0%) 38 (98%)